HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anthony P Adamis Selected Research

Leukostasis

2/2007Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.
9/2004A central role for inflammation in the pathogenesis of diabetic retinopathy.
8/2004Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy.
10/2003The role of advanced glycation end products in retinal microvascular leukostasis.
5/2003VEGF164 is proinflammatory in the diabetic retina.
3/2003Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Anthony P Adamis Research Topics

Disease

14Diabetic Retinopathy (Retinopathy, Diabetic)
01/2019 - 02/2002
13Macular Degeneration (Age-Related Maculopathy)
05/2022 - 03/2002
11Choroidal Neovascularization
05/2014 - 03/2002
9Macular Edema
05/2022 - 10/2005
7Inflammation (Inflammations)
01/2010 - 03/2002
6Corneal Neovascularization
02/2008 - 08/2002
6Leukostasis
02/2007 - 03/2003
5Pathologic Neovascularization
01/2016 - 06/2003
5Ischemia
07/2007 - 03/2002
4Neoplasms (Cancer)
01/2016 - 05/2003
4Retinal Neovascularization
04/2008 - 03/2002
3Retinal Detachment (Retinal Detachments)
01/2022 - 03/2002
3Hypoxia (Hypoxemia)
01/2016 - 03/2002
3Vascular Diseases (Vascular Disease)
10/2006 - 02/2004
2Retinal Diseases
05/2022 - 11/2020
2Vitreous Hemorrhage
01/2022 - 01/2019
2Endophthalmitis (Ophthalmia)
01/2022 - 10/2005
2Cicatrix (Scar)
01/2019 - 02/2010
2Colorectal Neoplasms (Colorectal Cancer)
01/2016 - 06/2005
2Edema (Dropsy)
05/2014 - 03/2002
2Retinal Vein Occlusion
08/2011 - 04/2009
2Blindness (Hysterical Blindness)
02/2005 - 06/2003
2Hyperglycemia
03/2003 - 03/2002
1Proliferative Vitreoretinopathy
02/2010
1Proteinuria
09/2007
1Reperfusion Injury
07/2007
1Glaucoma
03/2007
1Diabetes Mellitus
01/2006
1Choroid Diseases
02/2005
1Vascular Remodeling
06/2003
1Geographic Atrophy
05/2003
1Insulin Resistance
03/2003
1Lewis Lung Carcinoma
08/2002

Drug/Important Bio-Agent (IBA)

27Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2022 - 02/2002
15Retinaldehyde (Retinal)IBA
05/2014 - 03/2002
12pegaptanib (Macugen)FDA Link
01/2016 - 12/2004
6Ranibizumab (Lucentis)FDA Link
05/2022 - 08/2011
6Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
02/2007 - 05/2003
3Cell Adhesion MoleculesIBA
09/2004 - 04/2002
2Bevacizumab (Avastin)FDA Link
01/2016 - 06/2005
2JSM6427IBA
02/2010 - 10/2009
2Integrin alpha5beta1IBA
02/2010 - 10/2009
2CytokinesIBA
04/2008 - 09/2002
2Advanced Glycation End ProductsIBA
02/2007 - 10/2003
2Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA
08/2004 - 03/2002
2Protein Isoforms (Isoforms)IBA
05/2003 - 03/2003
2Insulin (Novolin)FDA Link
03/2003 - 03/2002
1Endothelial Growth FactorsIBA
05/2022
1Angiopoietin-2IBA
01/2016
1Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA
01/2016
1Bromodeoxyuridine (BrdU)IBA
02/2010
1Complement System Proteins (Complement)IBA
01/2010
1Drug CombinationsIBA
06/2009
11-phenyl-3,3-dimethyltriazene (PDT)IBA
02/2008
1Neuroprotective AgentsIBA
03/2007
1ErythropoietinFDA Link
03/2007
1Receptor for Advanced Glycation End ProductsIBA
02/2007
1Therapeutic UsesIBA
01/2007
1Nucleotide AptamersIBA
01/2007
1CollagenIBA
10/2006
1EpitopesIBA
10/2006
1Collagen Type IV (Type IV Collagen)IBA
10/2006
1Indicators and Reagents (Reagents)IBA
06/2006
1Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA
06/2006
1Biological ProductsIBA
02/2006
1salicylhydroxamic acid (SHAM)IBA
01/2006
1Fluorescein (Funduscein)FDA LinkGeneric
01/2006
1Neutralizing AntibodiesIBA
08/2004
1Insulin-Like Growth Factor I (IGF-1)IBA
08/2004
1NF-kappa B (NF-kB)IBA
08/2004
1Phosphotransferases (Kinase)IBA
08/2004
1Transcription Factor AP-1 (Transcription Factor AP 1)IBA
08/2004
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
02/2004
1DNA (Deoxyribonucleic Acid)IBA
10/2003
1Messenger RNA (mRNA)IBA
10/2003
1Clodronic Acid (Clodronate)IBA
08/2003
1Liposomes (Liposome)IBA
08/2003
1Chemokine ReceptorsIBA
07/2003
1LectinsIBA
05/2003
1Concanavalin AIBA
05/2003
1Dextrans (Dextran)FDA Link
05/2003
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
05/2003
1Retinal Pigments (Pigments, Visual)IBA
05/2003
1AntioxidantsIBA
03/2003
1Thioctic Acid (Lipoic Acid)IBA
03/2003
1Oxidants (Oxidizing Agents)IBA
03/2003
1Protein Kinase CIBA
03/2003
1Protein Kinase C betaIBA
03/2003
1alpha-TocopherolFDA Link
03/2003
1CCR ReceptorsIBA
02/2003
1Interleukin-1 (Interleukin 1)IBA
09/2002
1AngiostatinsIBA
08/2002
1AlkaliesIBA
08/2002

Therapy/Procedure

9Therapeutics
05/2022 - 03/2002
5Injections
08/2011 - 03/2002
3Intravitreal Injections
02/2010 - 03/2002
2Lasers (Laser)
01/2019 - 06/2003
1Operative Surgical Procedures
01/2019
1Intraocular Injections
08/2011
1Light Coagulation
01/2006